Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS) [PDF]
Background: We recently demonstrated that 48 h exposure of primary human bronchial epithelial (hBE) cells, obtained from both CF (F508del homozygous) and non-CF subjects, to the triple drug combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) results in a ...
Armirotti, Andrea +14 more
core +1 more source
Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndrome [PDF]
Julia Weitzel +4 more
openalex +1 more source
Clinical and Translational ScienceElexacaftor/tezacaftor/ivacaftor (ETI) significantly improves treatment outcomes for people with cystic fibrosis (pwCF) with at least one F508del allele. In 2023, the Food and Drug Administration approved ETI for children with CF aged 2–5 years. However,
Ngoc Hoa Truong +31 more
doaj +1 more source
Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study [PDF]
Francisco Hevilla +7 more
openalex +1 more source
Risk of weight gain due to the consumption of ultra-processed foods or Cystic Fibrosis Transmembrane Conductance Regulator modulator intake: Studies on the impact of protein content in ultra-processed foods and an inpatient rehabilitation programme in people with Cystic Fibrosis [PDF]
This doctoral thesis explores two critical risk factors for obesity: the consumption of ultra-processed foods (UPF) and the use of a novel pharmacological therapy in people with Cystic Fibrosis (CF).
Koop, Jana
core
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis [PDF]
Ryan Marsh +9 more
openalex +2 more sources
Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States [PDF]
Sonia Graziano +8 more
openalex +1 more source